- Home
- AMIX vs LUMO Comparison
AMIX vs LUMO Comparison
Compare AMIX & LUMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- LUMO
- Stock Information
- Founded
- AMIX 2014
- LUMO 2011
- Country
- AMIX United States
- LUMO United States
- Employees
- AMIX N/A
- LUMO N/A
- Industry
- AMIX
- LUMO Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- LUMO Health Care
- Exchange
- AMIX NYSE
- LUMO Nasdaq
- Market Cap
- AMIX 17.9M
- LUMO 28.8M
- IPO Year
- AMIX N/A
- LUMO N/A
- Fundamental
- Price
- AMIX $0.79
- LUMO $3.92
- Analyst Decision
- AMIX
- LUMO Strong Buy
- Analyst Count
- AMIX 0
- LUMO 2
- Target Price
- AMIX N/A
- LUMO $20.50
- AVG Volume (30 Days)
- AMIX 609.9K
- LUMO 168.7K
- Earning Date
- AMIX 11-02-2024
- LUMO 11-05-2024
- Dividend Yield
- AMIX N/A
- LUMO N/A
- EPS Growth
- AMIX N/A
- LUMO N/A
- EPS
- AMIX N/A
- LUMO N/A
- Revenue
- AMIX N/A
- LUMO $1,486,000.00
- Revenue This Year
- AMIX N/A
- LUMO $273.04
- Revenue Next Year
- AMIX N/A
- LUMO N/A
- P/E Ratio
- AMIX N/A
- LUMO N/A
- Revenue Growth
- AMIX N/A
- LUMO N/A
- 52 Week Low
- AMIX $0.51
- LUMO $1.37
- 52 Week High
- AMIX $7.60
- LUMO $4.55
- Technical
- Relative Strength Index (RSI)
- AMIX N/A
- LUMO 72.78
- Support Level
- AMIX N/A
- LUMO $3.39
- Resistance Level
- AMIX N/A
- LUMO $4.02
- Average True Range (ATR)
- AMIX 0.00
- LUMO 0.32
- MACD
- AMIX 0.00
- LUMO -0.04
- Stochastic Oscillator
- AMIX 0.00
- LUMO 90.24
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About LUMO Lumos Pharma Inc.
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.